毛利率近九成的减肥神药踏上资本旅途,银诺医药高开近三倍爆燃港股

星岛财经
Aug 15

《星岛》见习记者 黄冬艳 深圳报道经历三年资本寒冬的中国生物医药行业,终于在2025年迎来“盛夏”。继维立志博(9887.HK)、中慧生物(02627.HK)先后在港股获得超3000倍、超4000倍认购后,8月15日,银诺医药(02591.HK)也带着“超购王”第二的热度登陆港股市场。本次银诺医药全球发售共计3656万股H股,发售价为每股18.68港元,其中香港公开发售获得5341.66倍的超额...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10